Cubist Systematic Strategies LLC Acquires 7,735 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

Cubist Systematic Strategies LLC lifted its holdings in USANA Health Sciences, Inc. (NYSE:USNA) by 189.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,822 shares of the company’s stock after buying an additional 7,735 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.06% of USANA Health Sciences worth $535,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. CWM LLC raised its holdings in shares of USANA Health Sciences by 21.8% in the first quarter. CWM LLC now owns 1,543 shares of the company’s stock valued at $75,000 after buying an additional 276 shares during the last quarter. BOKF NA raised its holdings in shares of USANA Health Sciences by 274.5% in the first quarter. BOKF NA now owns 2,771 shares of the company’s stock valued at $133,000 after buying an additional 2,031 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in USANA Health Sciences by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after purchasing an additional 494 shares during the last quarter. DGS Capital Management LLC raised its holdings in USANA Health Sciences by 61.8% during the 1st quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock worth $352,000 after purchasing an additional 2,773 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in USANA Health Sciences during the 2nd quarter worth about $340,000. 54.25% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Gilbert A. Fuller sold 674 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Paul A. Jones sold 6,266 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gilbert A. Fuller sold 674 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total value of $26,751.06. The disclosure for this sale can be found here. Insiders sold a total of 7,940 shares of company stock valued at $311,670 in the last ninety days. 0.33% of the stock is owned by insiders.

USANA Health Sciences Price Performance

Shares of USNA stock opened at $35.79 on Friday. The stock has a market cap of $681.80 million, a PE ratio of 12.51, a price-to-earnings-growth ratio of 1.20 and a beta of 0.89. The stock has a 50-day moving average of $38.47 and a 200-day moving average of $43.18. USANA Health Sciences, Inc. has a one year low of $34.76 and a one year high of $57.78.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.11). The company had revenue of $212.87 million during the quarter, compared to the consensus estimate of $218.64 million. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. During the same period last year, the company earned $0.89 earnings per share. As a group, research analysts anticipate that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on the company. DA Davidson dropped their price objective on USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, July 25th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.